X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (132) 132
male (98) 98
middle aged (89) 89
female (86) 86
aged (83) 83
index medicus (74) 74
risk factors (65) 65
cardiac & cardiovascular systems (44) 44
medicine, general & internal (42) 42
clinical trials (37) 37
double-blind method (37) 37
cardiovascular diseases (36) 36
cardiovascular disease (35) 35
abridged index medicus (33) 33
peripheral vascular disease (32) 32
follow-up studies (31) 31
risk (31) 31
treatment outcome (31) 31
hypertension (30) 30
prevention (29) 29
article (27) 27
diabetes (26) 26
drug therapy (26) 26
mortality (26) 26
antihypertensive agents - therapeutic use (25) 25
hypertension - drug therapy (25) 25
cholesterol (24) 24
cardiovascular diseases - prevention & control (21) 21
disease (21) 21
angiotensin-converting enzyme inhibitors - therapeutic use (20) 20
drug therapy, combination (19) 19
stroke (19) 19
adult (18) 18
cardiovascular (18) 18
diabetes mellitus, type 2 - drug therapy (18) 18
proportional hazards models (18) 18
therapy (17) 17
atherosclerosis (16) 16
care and treatment (16) 16
heart failure (16) 16
hypertension - complications (16) 16
type 2 diabetes (16) 16
aged, 80 and over (15) 15
analysis (15) 15
hypolipidemic agents - therapeutic use (15) 15
myocardial-infarction (15) 15
cardiovascular diseases - epidemiology (14) 14
diabetes mellitus, type 2 - complications (14) 14
dosage and administration (14) 14
endocrinology & metabolism (14) 14
glucose (14) 14
health aspects (14) 14
incidence (14) 14
research (14) 14
trial (14) 14
blood pressure (13) 13
cardiovascular diseases - drug therapy (13) 13
cardiovascular diseases - mortality (13) 13
chlorthalidone - therapeutic use (13) 13
events (13) 13
heart attacks (13) 13
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (13) 13
risk assessment (13) 13
kaplan-meier estimate (12) 12
patients (12) 12
prevalence (12) 12
risk-factors (12) 12
time factors (12) 12
hypercholesterolemia (11) 11
hypoglycemic agents - therapeutic use (11) 11
myocardial infarction (11) 11
outcomes (11) 11
prospective studies (11) 11
randomized controlled trials as topic (11) 11
regression analysis (11) 11
united states (11) 11
association (10) 10
cardiology (10) 10
cardiovascular-disease (10) 10
cerebral infarction (10) 10
coronary-heart-disease (10) 10
diabetes mellitus (10) 10
lipids (10) 10
medical research (10) 10
progression (10) 10
research design (10) 10
secondary prevention (10) 10
amlodipine - therapeutic use (9) 9
benzimidazoles - therapeutic use (9) 9
coronary disease - prevention & control (9) 9
follow-up (9) 9
insulin (9) 9
lipid-lowering treatment (9) 9
lipoproteins (9) 9
lisinopril - therapeutic use (9) 9
medicine, research & experimental (9) 9
mellitus (9) 9
myocardial infarction - prevention & control (9) 9
telmisartan (9) 9
united states - epidemiology (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Health Services Research, ISSN 1472-6963, 07/2016, Volume 16, Issue 1, p. 236
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 03/2016, Volume 374, Issue 11, pp. 1095 - 1096
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 23, pp. 2247 - 2257
In this randomized study, the addition of lixisenatide, a glucagon-like peptide 1–receptor agonist, to usual care in patients with type 2 diabetes and a recent... 
MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | MYOCARDIAL-INFARCTION | CARDIOVASCULAR OUTCOMES | RECEPTOR AGONISTS | GLUCOSE | DOUBLE-BLIND | FOLLOW-UP | MELLITUS | CONGESTIVE-HEART-FAILURE | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Male | Acute Coronary Syndrome - drug therapy | Myocardial Infarction - complications | Acute Coronary Syndrome - complications | Angina, Unstable - complications | Diabetes Mellitus, Type 2 - mortality | Treatment Failure | Cardiovascular Diseases - epidemiology | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - adverse effects | Peptides - therapeutic use | Type 2 diabetes | Treatment outcome | Care and treatment | Analysis | Hypoglycemic agents | Dosage and administration | Acute coronary syndrome | Myocardial infarction | Cerebral infarction | Glucagon | Diabetes mellitus | Hypersensitivity | Pancreatitis | Angina | Glucose | Hypoglycemia | Morbidity | Studies | Heart rate | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Pancreas | Drug therapy | Diabetes mellitus (non-insulin dependent) | Heart diseases | Glucagon-like peptide 1 | Clinical trials | Regulatory approval | Hemoglobin | Drug dosages | Heart failure | Mortality
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 15, pp. 1383 - 1392
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 24, pp. 2255 - 2267
In this clinical trial involving patients with established cardiovascular disease, the addition of niacin to intensive statin therapy provided no additional... 
LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | DENSITY-LIPOPROTEIN CHOLESTEROL | IMPACT | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | CORONARY-HEART-DISEASE | COMBINATION | ARTERIAL BIOLOGY | EXTENDED-RELEASE NIACIN | SECONDARY PREVENTION | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Niacin - therapeutic use | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Brain Ischemia - chemically induced | Muscular Diseases - chemically induced | Drug Therapy, Combination | Brain Ischemia - epidemiology | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Atherosclerosis - blood | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cholesterol, HDL - blood | Aged | Hypolipidemic Agents - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Control | Dosage and administration | Product/Service Evaluations | Drug therapy | Niacin | Cholesterol | Statins | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Simvastatin | Cardiovascular disease | Triglycerides | Coronary artery disease | Ischemia | Diet | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Lipoproteins (high density) | Heart diseases
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 03/2012, Volume 366, Issue 13, pp. 1255 - 1256
Journal Article
JAMA, ISSN 0098-7484, 10/2011, Volume 306, Issue 16, pp. 1798 - 1799
Journal Article
JAMA, ISSN 0098-7484, 01/2009, Volume 301, Issue 1, pp. 39 - 51
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/1991, Volume 265, Issue 24, pp. 3255 - 3264
Objective.—To assess the ability of antihypertensive drug treatment to reduce the risk of nonfatal and fatal (total) stroke in isolated systolic... 
MORTALITY | TRIAL | POPULATION | MEDICINE, GENERAL & INTERNAL | OSLO | RISK | CARE | Hypertension | Stroke (Disease) | Prevention | Evaluation | Chlorthalidone | Demographic aspects | Antihypertensive drugs
Journal Article